Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Bluecrux's digital supply chain twin technology, Axon, plays a critical role in Sanofi's digital supply chain transformation.
The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
Subscribe To Our Newsletter & Stay Updated
